EXCLUSIVE DEVELOPMENT AND DISTRIBUTION AGREEMENTExclusive Development and Distribution Agreement • August 11th, 2022 • NEUROONE MEDICAL TECHNOLOGIES Corp • Surgical & medical instruments & apparatus
THIS THIRD AMENDMENT TO EXCLUSIVE DEVELOPMENT AND DISTRIBUTION AGREEMENT (this “Amendment”) is entered into as of August 2, 2022 (the “Effective Date”), by and between Zimmer, Inc., a Delaware corporation (“Zimmer”), and NeuroOne Medical Technologies Corporation, a Delaware corporation (the “Company”). Zimmer and the Company are referred to individually as a “Party” and together as the “Parties.”
Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is of the type that the Company treats as private or confidential. Double asterisks denote omissions. amended and restated EXCLUSIVE...Exclusive Development and Distribution Agreement • October 31st, 2024 • NEUROONE MEDICAL TECHNOLOGIES Corp • Surgical & medical instruments & apparatus • Indiana
This Amended and Restated Exclusive Development and Distribution Agreement (this “Agreement”) is entered into as of October 25, 2024 (the “Effective Date”), by and between Zimmer, Inc., a Delaware corporation (“Zimmer”), and NeuroOne Medical Technologies Corporation, a Delaware corporation (the “Company”). Zimmer and the Company are referred to individually as a “Party” and together as the “Parties”. Capitalized terms used herein, to the extent not otherwise defined, have the meanings specified in Exhibit A.
EXCLUSIVE DEVELOPMENT AND DISTRIBUTION AGREEMENTExclusive Development and Distribution Agreement • August 11th, 2022 • NEUROONE MEDICAL TECHNOLOGIES Corp • Surgical & medical instruments & apparatus
THIS SECOND AMENDMENT TO EXCLUSIVE DEVELOPMENT AND DISTRIBUTION AGREEMENT (this “Amendment”) is made as of this 28th day of June, 2022, with an effective date of July 1, 2022 (“Effective Date”), between Zimmer, Inc., a Delaware corporation (“Zimmer”), and NeuroOne Medical Technologies Corporation, a Delaware corporation (the “Company”). Zimmer and the Company are referred to individually as a “Party” and together as the “Parties”.
CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT BOTH (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED EXCLUSIVE DEVELOPMENT AND DISTRIBUTION AGREEMENTExclusive Development and Distribution Agreement • November 7th, 2024 • AVITA Medical, Inc. • Surgical & medical instruments & apparatus • New York
THIS EXCLUSIVE DEVELOPMENT AND DISTRIBUTION AGREEMENT (this “Agreement”) is made and entered into effective as of the 31st day of July 2024 (the “Effective Date”), by and between Collagen Matrix, Inc. dba Regenity Biosciences (“Regenity”), having its principal offices at [******], and AVITA Medical, Inc. (“Distributor”) having its principal offices at 28159 Avenue Stanford, Suite 220, Valencia, CA USA. Regenity and Distributor are referred to herein collectively as the “Parties,” and individually as a “Party.”
